CAMP4 THERAPEUTICS CORPORATION (CAMP) - Total Liabilities
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has total liabilities worth $70.10 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CAMP cash generation efficiency to assess how effectively this company generates cash.
CAMP4 THERAPEUTICS CORPORATION - Total Liabilities Trend (1985–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's total liabilities have evolved over time, based on quarterly financial data. Check CAMP4 THERAPEUTICS CORPORATION liquid asset ratio to evaluate the company's liquid asset resilience ratio.
CAMP4 THERAPEUTICS CORPORATION Competitors by Total Liabilities
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
USA | $2.48 Billion |
|
Astral Resources NL
AU:AAR
|
Australia | AU$4.49 Million |
|
Kardan Israel Ltd
TA:KRDI
|
Israel | ILA2.29 Billion |
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
USA | $1.93 Million |
|
Thayer Ventures Acquisition Corporation II Class A Ordinary Shares
NASDAQ:TVAI
|
USA | $8.51 Million |
|
Honghua Group Limited
F:4HB
|
Germany | €9.06 Billion |
|
Monument Mining Limited
V:MMY
|
Canada | CA$22.55 Million |
|
Solvar Ltd
AU:SVR
|
Australia | AU$624.70 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down CAMP4 THERAPEUTICS CORPORATION's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CAMP4 THERAPEUTICS CORPORATION market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CAMP4 THERAPEUTICS CORPORATION's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CAMP4 THERAPEUTICS CORPORATION (1985–2025)
The table below shows the annual total liabilities of CAMP4 THERAPEUTICS CORPORATION from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $70.10 Million | +362.34% |
| 2024-12-31 | $15.16 Million | -91.51% |
| 2023-12-31 | $178.68 Million | -0.78% |
| 2022-12-31 | $180.08 Million | -44.09% |
| 2021-12-31 | $322.11 Million | -5.95% |
| 2020-12-31 | $342.50 Million | -4.30% |
| 2019-12-31 | $357.89 Million | -10.07% |
| 2018-12-31 | $397.97 Million | +45.20% |
| 2017-12-31 | $274.08 Million | +12.47% |
| 2016-12-31 | $243.68 Million | +25.02% |
| 2015-12-31 | $194.92 Million | +280.46% |
| 2014-12-31 | $51.23 Million | +11.09% |
| 2013-12-31 | $46.12 Million | +38.82% |
| 2012-12-31 | $33.22 Million | +25.35% |
| 2011-12-31 | $26.50 Million | -30.04% |
| 2010-12-31 | $37.88 Million | +0.34% |
| 2009-12-31 | $37.75 Million | -18.72% |
| 2008-12-31 | $46.45 Million | -33.28% |
| 2007-12-31 | $69.62 Million | -11.26% |
| 2006-12-31 | $78.45 Million | +177.83% |
| 2005-12-31 | $28.24 Million | -26.59% |
| 2004-12-31 | $38.47 Million | +19.17% |
| 2003-12-31 | $32.28 Million | +4.21% |
| 2002-12-31 | $30.97 Million | +62.10% |
| 2001-12-31 | $19.11 Million | -2.17% |
| 2000-12-31 | $19.53 Million | -28.87% |
| 1999-12-31 | $27.46 Million | +418.08% |
| 1998-12-31 | $5.30 Million | -13.11% |
| 1997-12-31 | $6.10 Million | +12.96% |
| 1996-12-31 | $5.40 Million | -44.33% |
| 1995-12-31 | $9.70 Million | +34.72% |
| 1994-12-31 | $7.20 Million | -2.70% |
| 1993-12-31 | $7.40 Million | -14.94% |
| 1992-12-31 | $8.70 Million | +61.11% |
| 1991-12-31 | $5.40 Million | +92.86% |
| 1990-12-31 | $2.80 Million | -28.21% |
| 1989-12-31 | $3.90 Million | +39.29% |
| 1988-12-31 | $2.80 Million | -48.15% |
| 1987-12-31 | $5.40 Million | 0.00% |
| 1986-12-31 | $5.40 Million | -38.64% |
| 1985-12-31 | $8.80 Million | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics C… Read more